Ginkgo Bioworks
http://www.ginkgobioworks.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ginkgo Bioworks
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
Synthetic Biology Matures, Promising Affordable And Personalized Treatments
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Ginkgo Bioworks, Boehringer Enter Into Drug Discovery Partnership
Deal Snapshot: Ginkgo will earn up to $406m in fees plus royalties as it works with Boehringer Ingelheim to mine its metagenomics database for drug candidates.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice